Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement

Published on Mar 1, 2018in European Respiratory Journal16.671
· DOI :10.1183/13993003.00170-2018
Jakko van Ingen50
Estimated H-index: 50
(Radboud University Nijmegen),
Timothy R. Aksamit29
Estimated H-index: 29
(Mayo Clinic)
+ 20 AuthorsDirk Wagner40
Estimated H-index: 40
(University of Freiburg)
Sources
Abstract
Improving treatment outcome reporting in NTM disease: NTM-NET (@ntmnet) consensus statement on treatment outcome definitions http://ow.ly/c6IC30iwLM4
📖 Papers frequently viewed together
20179.25Thorax
20189.41Chest
References19
Newest
#1Charles S. Haworth (Papworth Hospital)H-Index: 34
#2John Banks (Abertawe Bro Morgannwg University Health Board)H-Index: 5
Last. R. Andres Floto (University of Cambridge)H-Index: 34
view all 16 authors...
Section 4: What is the evidence for transmission of NTM between individuals? Recommendation Section 5: How should the lung disease attributable to NTM infection be defined? Recommendation Good practice point Section 6: What samples should be used to detect pulmonary non-tuberculous mycobacterial infection? Recommendations Good practice points Section …
Source
#1Charles S. Haworth (Papworth Hospital)H-Index: 34
#2John Banks (Abertawe Bro Morgannwg University Health Board)H-Index: 5
Last. R. Andres FlotoH-Index: 34
view all 16 authors...
The full guideline for the management of non-tuberculous mycobacterial pulmonary disease is published in Thorax . The following is a summary of the recommendations and good practice points. The sections referred to in the summary refer to the full guideline.
Source
#1Sanne M.H. Zweijpfenning (Radboud University Nijmegen)H-Index: 7
#2Stephan Kops (Radboud University Nijmegen)H-Index: 2
Last. Wouter Hoefsloot (Radboud University Nijmegen)H-Index: 20
view all 6 authors...
Abstract Background The incidence of non-tuberculous mycobacterial pulmonary disease (NTM-PD) has increased in the Netherlands. The fibro-cavitary disease manifestation predominates, as elsewhere in Europe. We studied treatment and outcome of this disease manifestation, as such data are scarce. Methods We conducted a retrospective study of all patients diagnosed with NTM-PD according to the American Thoracic Society statement between 2008 and 2013 in a reference clinic. Results Sixty-three patie...
Source
#1BR O’Driscoll (University of Salford)H-Index: 6
#2Luke Howard (Imperial College Healthcare)H-Index: 41
Last. V Mak (Imperial College Healthcare)H-Index: 1
view all 4 authors...
Abbreviations and symbols used in this guideline Executive summary Summary of recommendations Section 1 Introduction Section 2 Methodology of guideline production Section 3 Normal values and definitions
Source
#1Kenneth N. Olivier (NIH: National Institutes of Health)H-Index: 67
#2David E. Griffith (UT Tyler: University of Texas at Tyler)H-Index: 5
Last. Richard J. Wallace (UT Tyler: University of Texas at Tyler)H-Index: 103
view all 16 authors...
Rationale: Lengthy, multidrug, toxic, and low-efficacy regimens limit management of pulmonary nontuberculous mycobacterial disease.Objectives: In this phase II study, we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatment-refractory pulmonary nontuberculous mycobacterial (Mycobacterium avium complex [MAC] or Mycobacterium abscessus) disease.Methods: During the double-blind phase, patients were randomly assigned to LAI (590 mg) or placebo once daily added ...
Source
#1Gunar GuentherH-Index: 7
#2Christoph LangeH-Index: 105
Last. Frank van LethH-Index: 24
view all 29 authors...
Multidrug-resistant tuberculosis is a major global challenge. This report examines the definition of treatment success and its effect on determining cure.
Source
#1Vanessa Deggim-Messmer (UZH: University of Zurich)H-Index: 1
#2Guido V. Bloemberg (UZH: University of Zurich)H-Index: 68
Last. Erik C. Böttger (UZH: University of Zurich)H-Index: 84
view all 7 authors...
Molecular assays have not yet been able to replace time-consuming culture-based methods in clinical mycobacteriology. Using 6875 clinical samples and a study period of 35 months we evaluated the use of PCR-based assays to establish a diagnostic workflow with a fast time-to-result of 1–2 days, for 1. detection of Mycobacterium tuberculosis complex (MTB), 2. detection and identification of nontuberculous mycobacteria (NTM), and 3. identification of drug susceptible MTB. MTB molecular-based detecti...
Source
#1Jason E. Stout (Duke University)H-Index: 34
#2Won-Jung Koh (SMC: Samsung Medical Center)H-Index: 69
Last. Wing Wai Yew (CUHK: The Chinese University of Hong Kong)H-Index: 27
view all 3 authors...
Non-tuberculous mycobacteria (NTM) are emerging worldwide as significant causes of chronic pulmonary infection, posing a number of challenges for both clinicians and researchers. While a number of studies worldwide have described an increasing prevalence of NTM pulmonary disease over time, population-based data are relatively sparse and subject to ascertainment bias. Furthermore, the disease is geographically heterogeneous. While some species are commonly implicated worldwide (Mycobacterium aviu...
Source
#1Tomasz Jagielski (University of Warsaw)H-Index: 20
#2Alina Minias (PAN: Polish Academy of Sciences)H-Index: 8
Last. Jarosław Dziadek (PAN: Polish Academy of Sciences)H-Index: 30
view all 7 authors...
Molecular typing has revolutionized epidemiological studies of infectious diseases, including those of a mycobacterial etiology. With the advent of fingerprinting techniques, many traditional concepts regarding transmission, infectivity, or pathogenicity of mycobacterial bacilli have been revisited, and their conventional interpretations have been challenged. Since the mid-1990s, when the first typing methods were introduced, a plethora of other modalities have been proposed. So-called molecular...
Source
Rationale: Mycobacterium abscessus group lung infection is characterized by low cure rates. Improvement in quality of life may be a reasonable treatment goal.Objectives: The objective of this study was to evaluate change in quality of life in response to therapy, predictors of improvement in quality of life, and association of quality of life with traditional outcome measures.Methods: Forty-seven patients were treated for Mycobacterium abscessus group lung infection (including one with Mycobacte...
Source
Cited By79
Newest
#1Jakko van Ingen (Radboud University Nijmegen)H-Index: 50
Last. Charles L. Daley (University of Colorado Denver)H-Index: 71
view all 7 authors...
Introduction null Nontuberculous mycobacterial (NTM) lung disease (LD) is the most common clinical manifestation of NTM infection and is a growing health concern. Up to 85% of NTM-LD cases are caused by Mycobacterium avium complex (MAC). Increased awareness of NTM-LD caused by MAC is needed as patients with this disease experience substantial burden and unmet treatment needs. null Areas covered null This review provides clinicians and regulatory and healthcare decision makers an overview of the ...
Source
#1Herman PfaeffleH-Index: 1
#2Reem Alameer (UVA: University of Virginia)
Last. Scott K. Heysell (UVA: University of Virginia)H-Index: 21
view all 6 authors...
Abstract null null Background:/Question null Nontuberculous mycobacteria (NTM) infections are increasingly detected but difficult to cure given complex drug-resistance patterns. Select U.S. centers have incorporated null clofazimine null null in the treatment of null NTM null but experience is limited as procurement restrictions hamper widespread use. null null null null Methods null null A null prospective cohort study null was performed in patients diagnosed with pulmonary or extrapulmonary NT...
Source
#1Kiyoharu Fukushima (Osaka University)H-Index: 6
#2Seigo KitadaH-Index: 17
Last. Mari MikiH-Index: 13
view all 13 authors...
Abstract null null Background null No objective serum biomarkers of disease course or treatment outcome of Mycobacterium avium complex lung disease (MAC-LD) presently exist. Serum IgA antibody levels against the glycopeptidolipid (GPL) core have good diagnostic accuracy for MAC-LD. However, their usefulness for monitoring and predicting disease course and outcome of MAC-LD following first-line antibiotic treatment remains unclear. null null null Methods null We conducted a single-center retrospe...
Source
#1Rabi Danho (Radboud University Nijmegen)H-Index: 1
#2Jodie A Schildkraut (Radboud University Nijmegen)H-Index: 5
Last. Jakko van Ingen (Radboud University Nijmegen)H-Index: 50
view all 10 authors...
Source
#1Takahiro Ando (UTokyo: University of Tokyo)H-Index: 7
#2Hidenori Kage (UTokyo: University of Tokyo)H-Index: 14
Last. Takahide Nagase (UTokyo: University of Tokyo)H-Index: 44
view all 5 authors...
Abstract null null Background null Ethambutol ocular toxicity is a major problem during combination chemotherapy for Mycobacterium avium complex (MAC) pulmonary disease (MAC-PD) due to years-long therapy for MAC. null null null Objectives null This study aimed to identify the lower dose of daily ethambutol that can reduce ocular toxicity. null null null Methods null We retrospectively reviewed the medical records of 312 patients who visited The University of Tokyo Hospital between January 2007 a...
Source
#5Nakwon Kwak (Seoul National University Hospital)H-Index: 10
Introduction null The lack of reliable predictors for the treatment response complicates decisions to initiate treatment in patients with Mycobacterium abscessus complex pulmonary disease (MABC-PD). We aimed to investigate whether baseline radiographic disease severity is associated with treatment outcome in MABC-PD. null Method null We retrospectively analyzed 101 patients with MABC-PD (54 with M. abscessus-PD and 47 with M. massiliense-PD) treated in a tertiary referral hospital between Januar...
Source
#1Jelmer Raaijmakers (Radboud University Nijmegen)
#2Jodie A Schildkraut (Radboud University Nijmegen)H-Index: 5
Last. Jakko van Ingen (Radboud University Nijmegen)H-Index: 50
view all 4 authors...
Introduction: Guidelines recommend the use of amikacin in the treatment of nontuberculous mycobacterial (NTM) disease. The authors have evaluated the evidence for the position of amikacin in NTM disease treatment.Areas covered: The authors performed a literature search for original research on amikacin in NTM disease, including its mechanism of action, emergence of resistance, pre-clinical and clinical investigations.Expert opinion: Amikacin shows moderate in vitro activity against the clinicall...
Source
#1Ko Harada (Okayama University)H-Index: 6
#2Hideharu Hagiya (Okayama University)H-Index: 13
Last. Fumio Otsuka (Okayama University)H-Index: 36
view all 6 authors...
BACKGROUND The incidence of nontuberculous mycobacterial (NTM) infections has been increasing worldwide, becoming a significant healthcare burden especially among elderly people. This study aimed to evaluate the trends in NTM-associated mortality in Japan. METHODS This study used vital statistics data and data on all NTM-associated deaths (N=18,814) among individuals aged ≥40 years in Japan from 1997 to 2016. We calculated the crude and age-adjusted mortality rates by age and sex and used joinpo...
Source
#1Kevin L. Winthrop (OHSU: Oregon Health & Science University)H-Index: 72
#2Patrick A. Flume (MUSC: Medical University of South Carolina)H-Index: 52
Last. David E. Griffith (University of Texas Health Science Center at Tyler)H-Index: 61
view all 16 authors...
Rationale: Patients with refractory Mycobacterium avium complex (MAC) lung disease have limited treatment options. In the CONVERT study, amikacin liposome inhalation suspension (ALIS) added to guid...
Source
#8Nakwon Kwak (Seoul National University Hospital)H-Index: 10
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.